Cited by 683Histone Deacetylase Inhibitors ResearchAdvanced Proteomics Techniques and ApplicationsMass Spectrometry Techniques and Applications

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

Bantscheff, Marcus, Hopf, Carsten, Savitski, Mikhail M, Dittmann, Antje, Grandi, Paola, Michon, Anne-Marie, Schlegl, Judith, Abraham, Yann, Becher, Isabelle, Bergamini, Giovanna, Boesche, Markus, Delling, Manja, Dümpelfeld, Birgit, Eberhard, Dirk, Huthmacher, Carola, Mathieson, Toby, Poeckel, Daniel, Reader, Valérie, Strunk, Katja, Sweetman, Gavain, Kruse, Ulrich, Neubauer, Gitte, Ramsden, Nigel G, Drewes, Gerard·2011·Nature Biotechnology

DOI 10.1038/nbt.1759

Open this paper in CoChat — free account

Abstract

The development of selective histone deacetylase (HDAC) inhibitors with anti-cancer and anti-inflammatory properties remains challenging in large part owing to the difficulty of probing the interaction of small molecules with megadalton protein complexes. A combination of affinity capture and quantitative mass spectrometry revealed the selectivity with which 16 HDAC inhibitors target multiple HDAC complexes scaffolded by ELM-SANT domain subunits, including a novel mitotic deacetylase complex (MiDAC). Inhibitors clustered according to their target profiles with stronger binding of aminobenzamides to the HDAC NCoR complex than to the HDAC Sin3 complex. We identified several non-HDAC targets for hydroxamate inhibitors. HDAC inhibitors with distinct profiles have correspondingly different effects on downstream targets. We also identified the anti-inflammatory drug bufexamac as a class IIb (HDAC6, HDAC10) HDAC inhibitor. Our approach enables the discovery of novel targets and inhibitors and suggests that the selectivity of HDAC inhibitors should be evaluated in the context of HDAC complexes and not purified catalytic subunits.

Integrity signals

Registry

Crossref · 10.1038/nbt.1759

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Proteome survey reveals modularity of the yeast cell machinery
Gavin, A., Aloy, P., Grandi, P., Krause, R., Böesche, M., Marzioch, M., Rau, C., Jensen, L. J., Bastuck, S., Dümpelfeld, B., et al. (2006) · Nature · doi:10.1038/nature04532 · Cited by 2,570
Self-citation
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,456
Regulation of cellular metabolism by protein lysine acetylation
Zhao, S., Xu, W., Jiang, W., Yu, W., Lin, Y., Zhang, T., Yao, J., Zhou, L., Zeng, Y., Li, H., et al. (2010) · Science · doi:10.1126/science.1179689 · Cited by 1,910
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Parts per Million Mass Accuracy on an Orbitrap Mass Spectrometer via Lock Mass Injection into a C-trap
Olsen, J. V., de Godoy, L. M. F., Li, G., Maček, B., Mortensen, P., Pesch, R., Makarov, A., Lange, O., Horning, S. R., & Mann, M. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t500030-mcp200 · Cited by 1,539
Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
The Cell as a Collection of Protein Machines: Preparing the Next Generation of Molecular Biologists
Alberts, B. (1998) · Cell · doi:10.1016/s0092-8674(00)80922-8 · Cited by 1,411

Show all 50 references

Sorted by citations

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,530
Self-citation
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Self-citation
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
HDACs and HDAC Inhibitors in Cancer Development and TherapyPreprint
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,337
Tracking cancer drugs in living cells by thermal profiling of the proteome
Savitski, M. M., Reinhard, F. B. M., Franken, H., Werner, T., Savitski, M. F., Eberhard, D., Molina, D. M., Jafari, R., Dovega, R. B., Klaeger, S., et al. (2014) · Science · doi:10.1126/science.1255784 · Cited by 1,187
Self-citation
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
Kruidenier, L., Chung, C.-W., Cheng, Z., Liddle, J., Che, K., Joberty, G., Bantscheff, M., Bountra, C., Bridges, A., Diallo, H., et al. (2012) · Nature · doi:10.1038/nature11262 · Cited by 950
Self-citation
Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present
Bantscheff, M., Lemeer, S., Savitski, M. M., & Kuster, B. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6203-4 · Cited by 801
Self-citation
Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry
Franken, H., Mathieson, T., Childs, D., Sweetman, G. M. A., Werner, T., Tögel, I., Doce, C., Gade, S., Bantscheff, M., Drewes, G., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.101 · Cited by 651
Self-citation
Histone deacetylases as regulators of inflammation and immunity
Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., & Sweet, M. J. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.04.001 · Cited by 546
Cancer biology and NuRD: a multifaceted chromatin remodelling complex
Lai, A. Y., & Wade, P. A. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3091 · Cited by 541
Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors
Delcuve, G. P., Khan, D. H., & Davie, J. R. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-5 · Cited by 505
Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms
Polprasert, C., Schulze, I., Sekeres, M. A., Makishima, H., Przychodzen, B. P., Hosono, N., Singh, J., Padgett, R. A., Gu, X., Phillips, J. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.017 · Cited by 443
Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
Milazzo, G., Mercatelli, D., Muzio, G. D., Triboli, L., Rosa, P. D., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 448
Metabolic control of epigenetics in cancer
Kinnaird, A. S., Zhao, S., Wellen, K. E., & Michelakis, E. D. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.82 · Cited by 429
Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages
Chen, X., Barozzi, I., Termanini, A., Prosperini, E., Recchiuti, A., Dalli, J., Mietton, F., Matteoli, G., Hiebert, S., & Natoli, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121131109 · Cited by 397
Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates
Millard, C. J., Watson, P. J., Celardo, I., Gordiyenko, Y., Cowley, S. M., Robinson, C. V., Fairall, L., & Schwabe, J. W. R. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.020 · Cited by 396
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
Lobera, M., Madauss, K. P., Pohlhaus, D. T., Wright, Q. G., Trocha, M., Schmidt, D. R., Baloglu, E., Trump, R. P., Head, M. S., Hofmann, G. A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1223 · Cited by 385
B cell-intrinsic epigenetic modulation of antibody responses by dietary fiber-derived short-chain fatty acids
Sanchez, H. N., Moroney, J. B., Gan, H., Shen, T., Im, J. L., Li, T., Taylor, J. R., Zan, H., & Casali, P. (2020) · Nature Communications · doi:10.1038/s41467-019-13603-6 · Cited by 369
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Guo, L., Tian, Y., & Zhu, W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 364
BLUEPRINT to decode the epigenetic signature written in blood
Adams, D., Altucci, L., Antonarakis, S., Ballesteros, J., Beck, S., Bird, A., Bock, C., Boehm, B., Campo, E., Caricasole, A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2153 · Cited by 374
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes‐McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 373
Self-citation
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia
Maes, T., Mascaró, C., Tirapu, I., Estiarte, A., Ciceri, F., Lunardi, S., Guibourt, N., Perdones, A., Lufino, M. M., Somervaille, T. C. P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.002 · Cited by 345
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases
Hull, E. E., Montgomery, M. R., & Leyva, K. J. (2016) · BioMed Research International · doi:10.1155/2016/8797206 · Cited by 319
Thermal proteome profiling monitors ligand interactions with cellular membrane proteins
Reinhard, F. B. M., Eberhard, D., Werner, T., Franken, H., Childs, D., Doce, C., Savitski, M. F., Huber, W. K., Bantscheff, M., Savitski, M. M., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3652 · Cited by 310
Self-citation
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M. I., Olzscha, H., & Thangue, N. B. L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 315
The functional interactome landscape of the human histone deacetylase family
Joshi, P., Greco, T. M., Guise, A. J., Luo, Y., Yu, F., Nesvizhskii, A. I., & Cristea, I. M. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.26 · Cited by 289
Target engagement and drug residence time can be observed in living cells with BRET
Robers, M. B., Dart, M. L., Woodroofe, C. C., Zimprich, C., Kirkland, T. A., Machleidt, T., Kupcho, K. R., Levin, S., Hartnett, J. R., Zimmerman, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms10091 · Cited by 281
HDAC8: a multifaceted target for therapeutic interventions
Chakrabarti, A., Oehme, I., Witt, O., Oliveira, G., Sippl, W., Romier, C., Pierce, R. J., & Jung, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.013 · Cited by 284
Measuring and Managing Ratio Compression for Accurate iTRAQ/TMT Quantification
Savitski, M. M., Mathieson, T., Zinn, N., Sweetman, G. M. A., Doce, C., Becher, I., Pachl, F., Küster, B., & Bantscheff, M. (2013) · Journal of Proteome Research · doi:10.1021/pr400098r · Cited by 284
Self-citation
Acetylation site specificities of lysine deacetylase inhibitors in human cells
Schölz, C., Weinert, B. T., Wagner, S., Beli, P., Miyake, Y., Qi, J., Jensen, L. J., Streicher, W. W., McCarthy, A. R., Westwood, N. J., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3130 · Cited by 273
Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase
Paquet, T., Manach, C. L., Cabrera, D. G., Younis, Y., Henrich, P. P., Abraham, T. S., Lee, M., Basak, R., Ghidelli, S., Lafuente-Monasterio, M. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9735 · Cited by 276
Self-citation
HDAC4 Governs a Transcriptional Program Essential for Synaptic Plasticity and Memory
Sando, R., Gounko, N., Pieraut, S., Liao, L., Yates, J., & Maximov, A. (2012) · Cell · doi:10.1016/j.cell.2012.09.037 · Cited by 274
Ion Coalescence of Neutron Encoded TMT 10-Plex Reporter Ions
Werner, T., Sweetman, G. M. A., Savitski, M. F., Mathieson, T., Bantscheff, M., & Savitski, M. M. (2014) · Analytical Chemistry · doi:10.1021/ac500140s · Cited by 259
Self-citation
Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat
Becher, I., Werner, T., Doce, C., Zaal, E. A., Tögel, I., Khan, C. A., Rueger, A., Muelbaier, M., Salzer, E., Berkers, C. R., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2185 · Cited by 251
Self-citation
Determining target engagement in living systems
Simon, G. M., Niphakis, M. J., & Cravatt, B. F. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1211 · Cited by 245
Insights into the activation mechanism of class I HDAC complexes by inositol phosphates
Watson, P. J., Millard, C. J., Riley, A. M., Robertson, N. S., Wright, L. C., Godage, H. Y., Cowley, S. M., Jamieson, A. G., Potter, B. V. L., & Schwabe, J. W. R. (2016) · Nature Communications · doi:10.1038/ncomms11262 · Cited by 244
Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition
Frost, J., Galdeano, C., Soares, P., Gadd, M. S., Grzes, K. M., Ellis, L. C. J., Epemolu, O., Shimamura, S., Bantscheff, M., Grandi, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms13312 · Cited by 247
Self-citation
Histone deacetylase 10 promotes autophagy-mediated cell survival
Oehme, I., Linke, J.-P., Böck, B. C., Milde, T., Lodrini, M., Hartenstein, B., Wiegand, I., Eckert, C., Roth, W., Kool, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300113110 · Cited by 221
Analyzing Protein–Protein Interaction Networks
Koh, G. C. K. W., Porras, P., Aranda, B., Hermjakob, H., & Orchard, S. E. (2012) · Journal of Proteome Research · doi:10.1021/pr201211w · Cited by 221
Protein-protein interaction networks: probing disease mechanisms using model systems
Kuzmanov, U., & Emili, A. (2013) · Genome Medicine · doi:10.1186/gm441 · Cited by 197
Drug discovery considerations in the development of covalent inhibitors
Mah, R., Thomas, J. R., & Shafer, C. M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.10.003 · Cited by 203
High-Resolution Enabled TMT 8-plexing
Werner, T., Becher, I., Sweetman, G. M. A., Doce, C., Savitski, M. M., & Bantscheff, M. (2012) · Analytical Chemistry · doi:10.1021/ac301553x · Cited by 194
Self-citation
How Chemoproteomics Can Enable Drug Discovery and Development
Moellering, R. E., & Cravatt, B. F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.001 · Cited by 182
Targeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Okoye-Okafor, U. C., Bartholdy, B., Cartier, J., Gao, E. N., Pietrak, B., Rendina, A. R., Rominger, C., Quinn, C., Smallwood, A., Wiggall, K. J., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1930 · Cited by 180
Self-citation
Genome-wide localization of small molecules
Anders, L., Guenther, M. G., Qi, J., Fan, Z. P., Marineau, J., Rahl, P. B., Lovén, J., Sigova, A. A., Smith, W. B., Lee, T. I., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2776 · Cited by 182
Mass Spectrometry-Based Proteomics in Preclinical Drug Discovery
Schirle, M., Bantscheff, M., & Küster, B. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.002 · Cited by 184
Self-citation
Identifying drug targets in tissues and whole blood with thermal-shift profiling
Perrin, J., Werner, T., Kurzawa, N., Rutkowska, A., Childs, D. D., Kalxdorf, M., Poeckel, D., Stonehouse, E., Strohmer, K., Heller, B., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0388-4 · Cited by 178
Self-citation
Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders
Ishoey, M., Chorn, S., Singh, N., Jaeger, M. G., Brand, M., Paulk, J., Bauer, S., Erb, M. A., Parapatics, K., Müller, A. C., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00969 · Cited by 177
Histone Deacetylase Inhibitors In The Treatment Of Cancer: Overview And Perspectives
Giannini, G., Cabri, W., Fattorusso, C., & Rodriquez, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.80 · Cited by 182
HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain
Denk, F., Huang, W. L., Sidders, B. S., Bithell, A., Crow, M., Grist, J., Sharma, S., Ziemek, D., Rice, A. S. C., Buckley, N. J., et al. (2013) · Pain · doi:10.1016/j.pain.2013.05.021 · Cited by 172
Identifying compound efficacy targets in phenotypic drug discovery
Schirle, M., & Jenkins, J. L. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.001 · Cited by 166
Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B
Chen, P., Chaikuad, A., Bamborough, P., Bantscheff, M., Bountra, C., Chung, C., Fedorov, O., Grandi, P., Jung, D. K., Leśniak, R. K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00209 · Cited by 168
Self-citation
Histone Deacetylases in Bone Development and Skeletal Disorders
Bradley, E. W., Shull, L. C., van Wijnen, A. J., McGee‐Lawrence, M. E., & Westendorf, J. J. (2015) · Physiological Reviews · doi:10.1152/physrev.00004.2015 · Cited by 163
Epigenetic drug discovery: breaking through the immune barrier
Tough, D. F., Tak, P. P., Tarakhovsky, A., & Prinjha, R. K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.185 · Cited by 163
Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson’s Disease-Related Toxicity in Human Neurons
Ramsden, N. G., Perrin, J., Ren, Z., Lee, B. D., Zinn, N., Dawson, V. L., Tam, D., Bova, M. P., Lang, M., Drewes, G., et al. (2011) · ACS Chemical Biology · doi:10.1021/cb2002413 · Cited by 158
Self-citation
Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation
Leus, N. G. J., Zwinderman, M. R. H., & Dekker, F. J. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.06.019 · Cited by 153
Histone deacetylase inhibitors in hematological malignancies and solid tumors
Chun, P. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0571-1 · Cited by 151
A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation
Bergamini, G., Bell, K., Shimamura, S., Werner, T., Cansfield, A. D., Müller, K., Perrin, J., Rau, C., Ellard, K., Hopf, C., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.957 · Cited by 146
Self-citation
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
Verza, F. A., Das, U., Fachin, A. L., Dimmock, J. R., & Marins, M. (2020) · Cancers · doi:10.3390/cancers12061664 · Cited by 149
Histone deacetylase function in CD4+ T cells
Ellmeier, W., & Seiser, C. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0037-z · Cited by 146
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis
Wyllie, S., Thomas, M. G., Patterson, S., Crouch, S., Rycker, M. D., Lowe, R., Gresham, S., Urbaniak, M. D., Otto, T. D., Stojanovski, L., et al. (2018) · Nature · doi:10.1038/s41586-018-0356-z · Cited by 146
Self-citation
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy
Spiegel, S., Milstien, S., & Grant, S. (2011) · Oncogene · doi:10.1038/onc.2011.267 · Cited by 146
Histone/protein deacetylases and T-cell immune responses
Akimova, T., Beier, U. H., Liu, Y., Wang, L., & Hancock, W. W. (2012) · Blood · doi:10.1182/blood-2011-10-292003 · Cited by 142
The structure of the core NuRD repression complex provides insights into its interaction with chromatin
Millard, C. J., Varma, N., Saleh, A., Morris, K. L., Watson, P. J., Bottrill, A. R., Fairall, L., Smith, C. J., & Schwabe, J. W. R. (2016) · eLife · doi:10.7554/elife.13941 · Cited by 146
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors
Bots, M. L., Verbrugge, I., Martin, B. P., Salmon, J. M., Ghisi, M., Baker, A., Stanley, K. L., Shortt, J., Ossenkoppele, G. J., Zuber, J. A., et al. (2014) · Blood · doi:10.1182/blood-2013-03-488114 · Cited by 129
Chemoproteomics and Chemical Probes for Target Discovery
Drewes, G., & Knapp, S. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.06.008 · Cited by 132
Self-citation
Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance
Robey, R. W., Chakraborty, A. R., Basseville, A., Luchenko, V. L., Bahr, J. C., Zhan, Z., & Bates, S. E. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200329f · Cited by 135
Histone Deacetylase Inhibitors Upregulate B Cell microRNAs That Silence AID and Blimp-1 Expression for Epigenetic Modulation of Antibody and Autoantibody Responses
White, C. A., Pone, E. J., Lam, T., Tat, C., Hayama, K. L., Li, G., Zan, H., & Casali, P. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401702 · Cited by 131
Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors
Kalin, J. H., & Bergman, J. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001659 · Cited by 131
Co-repressor, co-activator and general transcription factor: the many faces of the Sin3 histone deacetylase (HDAC) complex
Adams, G. E., Chandru, A., & Cowley, S. M. (2018) · Biochemical Journal · doi:10.1042/bcj20170314 · Cited by 131
The long non-coding RNA LncHDAC2 drives the self-renewal of liver cancer stem cells via activation of Hedgehog signaling
Wu, J., Zhu, P., Lu, T., Du, Y., Wang, Y., He, L., Ye, B., Liu, B., Yang, L., Wang, J., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.015 · Cited by 128
Profiling of Substrates for Zinc‐dependent Lysine Deacylase Enzymes: HDAC3 Exhibits Decrotonylase Activity In Vitro
Madsen, A. S., & Olsen, C. A. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203754 · Cited by 122
Identification of Histone Deacetylase Inhibitors with Benzoylhydrazide Scaffold that Selectively Inhibit Class I Histone Deacetylases
Wang, Y., Stowe, R. L., Pinello, C. E., Tian, G., Madoux, F., Li, D., Zhao, L. Y., Li, J.-L., Wang, Y., Wang, Y., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.12.015 · Cited by 122
“For example, whereas vorinostat exerts potent inhibition of all known HDAC complexes, aminobenzamides seem to show some selectivity against different complexes (Bantscheff et al., 2011).”
Chromatin as an expansive canvas for chemical biology
Fierz, B., & Muir, T. W. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.938 · Cited by 125
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance
Santoro, F., Botrugno, O. A., Zuffo, R. D., Pallavicini, I., Matthews, G. M., Cluse, L. A., Barozzi, I., Senese, S., Fornasari, L., Moretti, S., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461988 · Cited by 124
Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies
Fraczek, J., Bolleyn, J., Vanhaecke, T., Rogiers, V., & Vinken, M. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0983-3 · Cited by 119
Structural Basis and SAR for G007-LK, a Lead Stage 1,2,4-Triazole Based Specific Tankyrase 1/2 Inhibitor
Voronkov, A. E., Holsworth, D. D., Waaler, J., Wilson, S. R., Ekblad, B., Perdreau‐Dahl, H., Dinh, H., Drewes, G., Hopf, C., Morth, J. P., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4000566 · Cited by 119
Self-citation
The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains
Dittmann, A., Werner, T., Chung, C., Savitski, M. M., Savitski, M. F., Grandi, P., Hopf, C., Lindon, M. J., Neubauer, G., Prinjha, R. K., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400789e · Cited by 119
Self-citation
Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo
Wang, P., Joberty, G., Buist, A., Vanoosthuyse, A., Stancu, I., Vasconcelos, B., Pierrot, N., Faelth-Savitski, M., Kienlen‐Campard, P., Octave, J., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1663-9 · Cited by 120
Self-citation
HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: Where do we stand?
Whittle, N., & Singewald, N. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130233 · Cited by 117
Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases
Gupta, K. D., Shakespear, M. R., Iyer, A., Fairlie, D. P., & Sweet, M. J. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2015.46 · Cited by 116
Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target
Lechner, S., Malgapo, M. I. P., Grätz, C., Steimbach, R. R., Baron, A., Rüther, P. L., Nadal, S., Stumpf, C., Loos, C., Ku, X., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01015-5 · Cited by 121
The Ketone Metabolite β-Hydroxybutyrate Attenuates Oxidative Stress in Spinal Cord Injury by Suppression of Class I Histone Deacetylases
Kong, G., Huang, Z., Ji, W., Wang, X., Liu, J., Wu, X., Huang, Z., Li, R., & Zhu, Q. (2017) · Journal of Neurotrauma · doi:10.1089/neu.2017.5192 · Cited by 113
The NSL complex maintains nuclear architecture stability via lamin A/C acetylation
Karoutas, A., Szymanski, W. G., Rausch, T., Guhathakurta, S., Rog‐Zielinska, E. A., Peyronnet, R., Seyfferth, J., Chen, H., de Leeuw, R., Herquel, B., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0397-z · Cited by 117
Ion Mobility Tandem Mass Spectrometry Enhances Performance of Bottom-up Proteomics
Helm, D., Vissers, J. P. C., Hughes, C. J., Hahne, H., Ruprecht, B., Pachl, F., Grzyb, A., Richardson, K., Wildgoose, J. L., Maier, S. K., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.041038 · Cited by 111
Self-citation
The MiDAC histone deacetylase complex is essential for embryonic development and has a unique multivalent structure
Turnbull, R. E., Fairall, L., Saleh, A., Kelsall, E., Morris, K. L., Ragan, T. J., Savva, C. G., Chandru, A., Millard, C. J., Makarova, O. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17078-8 · Cited by 108
Delayed Fragmentation and Optimized Isolation Width Settings for Improvement of Protein Identification and Accuracy of Isobaric Mass Tag Quantification on Orbitrap-Type Mass Spectrometers
Savitski, M. M., Sweetman, G. M. A., Askenazi, M., Marto, J. A., Lang, M., Zinn, N., & Bantscheff, M. (2011) · Analytical Chemistry · doi:10.1021/ac201760x · Cited by 108
Self-citation
Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors
Koppel, I., & Timmusk, T. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.015 · Cited by 108
The nucleosome landscape of Plasmodium falciparum reveals chromatin architecture and dynamics of regulatory sequences
Kensche, P. R., Hoeijmakers, W. A. M., Toenhake, C. G., Bras, M., Chappell, L., Berriman, M., & Bártfai, R. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1214 · Cited by 108
Insights into neuroepigenetics through human histone deacetylase PET imaging
Wey, H., Gilbert, T. M., Zürcher, N. R., She, A., Bhanot, A., Taillon, B. D., Schroeder, F. A., Wang, C., Haggarty, S. J., & Hooker, J. M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf7551 · Cited by 108
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
Stojanovic, N., Hassan, Z., Wirth, M., Wenzel, P., Beyer, M., Schäfer, C., Brand, P., Kroemer, A., Stauber, R. H., Schmid, R. M., et al. (2016) · Oncogene · doi:10.1038/onc.2016.344 · Cited by 109
Proteomics-Based Methods for Discovery, Quantification, and Validation of Protein–Protein Interactions
Miteva, Y. V., Budayeva, H. G., & Cristea, I. M. (2013) · Analytical Chemistry · doi:10.1021/ac3033257 · Cited by 105
Plants Release Precursors of Histone Deacetylase Inhibitors to Suppress Growth of Competitors
Venturelli, S., Belz, R. G., Kämper, A., Berger, A., von Horn, K., Wegner, A., Böcker, A., Zabulon, G., Langenecker, T., Kohlbacher, O., et al. (2015) · The Plant Cell · doi:10.1105/tpc.15.00585 · Cited by 105
Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Cheng, J., Demeulemeester, J., Wedge, D. C., Vollan, H. K. M., Pitt, J. J., Russnes, H. G., Pandey, B. P., Nilsen, G., Nord, S., Bignell, G. R., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01355-0 · Cited by 106

Authors: Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., Boesche, M., Delling, M., Dümpelfeld, B., Eberhard, D., Huthmacher, C., Mathieson, T., Poeckel, D., Reader, V., Strunk, K., Sweetman, G., Kruse, U., Neubauer, G., Ramsden, N. G., & Drewes, G.
Corresponding author: Bantscheff, Marcus
Drewes, Gerard
ORCID: Bantscheff, Marcus
Hopf, Carsten
Savitski, Mikhail M
Dittmann, Antje
Grandi, Paola
Schlegl, Judith
Abraham, Yann
Becher, Isabelle
Bergamini, Giovanna
Eberhard, Dirk
Mathieson, Toby
Reader, Valérie
Sweetman, Gavain
Neubauer, Gitte
Ramsden, Nigel G
Drewes, Gerard
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2011-01-23
Volume: 29
Issue: 3
Pages: 255-265
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.1759
OpenAlex: W2007139310
Cited by: 659
References: 50
Citations by year: 2026: 15 · 2025: 32 · 2024: 25 · 2023: 33 · 2022: 40 · 2021: 37 · 2020: 33 · 2019: 37 · 2018: 33 · 2017: 46 · 2016: 69 · 2015: 68 · 2014: 54 · 2013: 58 · 2012: 49
FWCI: 24.95
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
Keywords: histone deacetylase inhibitors, chemoproteomics, hydroxamate inhibitors, bufexamac, HDAC6, HDAC10, drug selectivity, affinity capture
MeSH terms: Histone Deacetylases, Peptide Mapping, Mass Spectrometry, Protein Interaction Mapping, Proteomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks